Navelbine Disease Interactions
There are 6 disease interactions with Navelbine (vinorelbine).
- Pulmonary dysfunction
- Hepatic dysfunction
- Infections
- Myelosuppression
- Gastrointestinal disorders
- Peripheral neurotoxicity
Vinca alkaloids (applies to Navelbine) pulmonary dysfunction
Major Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment
Acute shortness of breath and bronchospasm, some severe and life-threatening, have been reported with the use of vinca alkaloids. These reactions were observed most often during combination therapy with mitomycin C, occurring within minutes to several hours after administration of the vinca alkaloid or up to 2 weeks following the mitomycin dose. Therapy with vinca alkaloids should be administered cautiously in patients with preexisting pulmonary dysfunction. Aggressive treatment may be necessary, including use of supplemental oxygen, bronchodilators, and/or corticosteroids. In patients who develop progressive dyspnea requiring chronic therapy, vinca alkaloid should not be readministered.
References
- "Product Information. Velban (vinblastine)." Lilly, Eli and Company PROD (2001):
- "Product Information. Oncovin (vincristine)." Lilly, Eli and Company PROD (2001):
- "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome PROD (2001):
Vinorelbine (applies to Navelbine) hepatic dysfunction
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Vinorelbine is extensively metabolized by the liver. The pharmacokinetic disposition of vinorelbine in patients with hepatic impairment has not been assessed. Therapy with vinorelbine should be administered cautiously and the dosage reduced in patients with compromised hepatic function.
References
- "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome PROD (2001):
Vinorelbine (applies to Navelbine) infections
Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Vinorelbine induces myelosuppression manifested by neutropenia, anemia and thrombocytopenia. The use of vinorelbine may be contraindicated in patients with known infectious diseases. Patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection. Close clinical monitoring of hematopoietic function is recommended.
References
- "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome PROD (2001):
Vinorelbine (applies to Navelbine) myelosuppression
Major Potential Hazard, High plausibility. Applicable conditions: Fever, Bone Marrow Depression/Low Blood Counts
The use of vinorelbine is contraindicated in patients with neutrophil counts < 1000/mm3. Vinorelbine induces dose-dependent myelosuppression, primarily neutropenia. Therapy with vinorelbine should be administered with extreme caution and dosage modification considered in patients whose bone marrow reserve may be depressed by prior chemotherapy or irradiation or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended.
References
- "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome PROD (2001):
Vinorelbine (applies to Navelbine) gastrointestinal disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Constipation
Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation occur in patients receiving vinorelbine injection. Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus, considering adequate dietary fiber intake, hydration and routine use of stool softeners. Caution and monitoring is advised in patients with history of gastrointestinal issues.
References
- "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome PROD (2001):
Vinorelbine (applies to Navelbine) peripheral neurotoxicity
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Peripheral Neuropathy
Sensory and motor neuropathies, including severe neuropathies, occur in patients receiving vinorelbine. Monitor patients for new or worsening signs and symptoms of neuropathy, such as paresthesia, hyperesthesia, hyporeflexia and muscle weakness while receiving vinorelbine. Discontinue vinorelbine for CTCAE Grade 2 or greater neuropathy. Therapy with vinorelbine should be administered cautiously in patients with or predisposed to neuropathy.
References
- "Product Information. Navelbine (vinorelbine)." Glaxo Wellcome PROD (2001):
Navelbine drug interactions
There are 470 drug interactions with Navelbine (vinorelbine).
More about Navelbine (vinorelbine)
- Navelbine consumer information
- Check interactions
- Compare alternatives
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: mitotic inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.